Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma
暂无分享,去创建一个
C. Perou | O. Olopade | G. Karaca | C. Livasy | M. Tretiakova | D. Moore | R. Nanda | D. Moore
[1] F. Rilke,et al. Vimentin and p53 expression on epidermal growth factor receptor-positive, oestrogen receptor-negative breast carcinomas. , 1988, British Journal of Cancer.
[2] E. Gelmann,et al. Vimentin rather than keratin expression in some hormone-independent breast cancer cell lines and in oncogene-transformed mammary epithelial cells. , 1989, Cancer research.
[3] G. Striker,et al. Vimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomas. , 1990, The American journal of pathology.
[4] M. Hendrix,et al. Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. , 1997, The American journal of pathology.
[5] S. Hirohashi,et al. Myoepithelial differentiation in high-grade invasive ductal carcinomas with large central acellular zones. , 1999, Human pathology.
[6] Christian A. Rees,et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[7] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[8] S. Hirohashi,et al. Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. , 2000, The American journal of surgical pathology.
[9] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[10] O. Dietze,et al. Co‐expression of tenascin‐C and vimentin in human breast cancer cells indicates phenotypic transdifferentiation during tumour progression: correlation with histopathological parameters, hormone receptors, and oncoproteins , 2001, The Journal of pathology.
[11] C. Sotiriou,et al. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer , 2002, Breast Cancer Research.
[12] J. Sng,et al. Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[14] Martin Eisenacher,et al. Cytogenetic Alterations and Cytokeratin Expression Patterns in Breast Cancer: Integrating a New Model of Breast Differentiation into Cytogenetic Pathways of Breast Carcinogenesis , 2002, Laboratory Investigation.
[15] R. Tibshirani,et al. Copyright © American Society for Investigative Pathology Short Communication Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome , 2022 .
[16] Yudong D. He,et al. A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .
[17] I. Andrulis,et al. HER‐2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry , 2002, Cancer.
[18] C. Perou,et al. Molecular portraits and the family tree of cancer , 2002, Nature Genetics.
[19] Van,et al. A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.
[20] M. West,et al. Gene expression predictors of breast cancer outcomes , 2003, The Lancet.
[21] Philip M. Long,et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[22] L. Bégin,et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. , 2004, Journal of the National Cancer Institute.
[23] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[24] A. Gown,et al. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.
[25] S. Shousha,et al. Myoepithelial markers are expressed in at least 29% of oestrogen receptor negative invasive breast carcinoma , 2004, Modern Pathology.
[26] William D. Foulkes,et al. Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer , 2004 .
[27] Wei Wang,et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. , 2004, Cancer cell.
[28] I. Ellis,et al. Expression of luminal and basal cytokeratins in human breast carcinoma , 2004, The Journal of pathology.
[29] Ian O Ellis,et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis , 2005, Modern Pathology.